Conditions
Carcinoma, Non-Small-Cell Lung
Researchers are looking for new ways to treat people with locally advanced non-small cell lung cancer (NSCLC). The goal of this study is to learn if people who receive the combination of vibostolimab and pembrolizumab (MK-7684A) live longer without the cancer getting worse and live longer overall than people who receive durvalumab.
CLINICALTRIALS.GOV IDENTIFIER
NCT05298423
EudraCT Number
2021-005135-23
EU CT Number
2022-502752-31-00
When you talk with your doctor or clinical trial team member, please have the trial identifier number available.
Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial. However, this information may be useful in starting a conversation with your doctor.
Conditions
Carcinoma, Non-Small-Cell Lung
Age Range
All Ages
Sex
All
All patients who enroll in the trial will receive medication while on the study.
50% of patients will receive treatment with MK-7684A plus concurrent chemoradiotherapy (cCRT) followed by treatment with MK-7684A alone.
50% of patients will receive treatment with cCRT followed by treatment with durvalumab.
*You, your trial doctor, and the trial staff will know what you are getting.
In Phase 3 trials, researchers try to find out if a treatment works in a large number of people, usually about 1,000 to 5,000 participantsResearch participantIn clinical research, a person who qualifies and agrees to participate in a study. Also called volunteer, trial participant. who have the health condition the treatment is intended to treat. In vaccine trials, the participants may be healthy or have diseases or conditions. Phase 3 trials may happen in a doctor’s office, a clinic, or a hospital.
Sorry, there are no locations found.
If you think this clinical trial might be a good fit and you are interested in taking part, take the next step to see if you are eligible.
If you are considering joining a clinical trial, first learn as much as you can about:
Talk to your doctor about the clinical trial before you decide to join.
Read our “What to Consider” page for more questions to ask and think about